search
Back to results

Dopamine Release to Food Reward in Bulimia Nervosa

Primary Purpose

Bulimia Nervosa, Food Reward

Status
Unknown status
Phase
Not Applicable
Locations
Belgium
Study Type
Interventional
Intervention
Food reward at baseline
Food reward after treatment
Sponsored by
Universitaire Ziekenhuizen KU Leuven
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Bulimia Nervosa focused on measuring Bulimia Nervosa, Eating disorder, Dopamine, Food, Reward, Positron Emission Tomography, Magnetic Resonance, Metabolic hormones

Eligibility Criteria

18 Years - 50 Years (Adult)FemaleAccepts Healthy Volunteers

Patients with Bulimia Nervosa:

Inclusion Criteria:

  • Diagnosed with Bulimia Nervosa based on DSM-5 criteria;
  • Admission for inpatient treatment;
  • Female (on hormonal contraception);
  • Dutch-speaking;
  • Right-handed;
  • Body Mass Index (BMI) of 18.5 - 25 kg/m².

Exclusion Criteria:

  • Medical, neurological or other psychiatric disorders;
  • Use of psychotropic medication in past 6 months;
  • Use of cannabis or other drugs of abuse in past 12 months;
  • Lactose-intolerance or food allergies;
  • Vegetarian diet;
  • Smoking;
  • Consumption of more than 7 alcoholic units per week;
  • Exposure to a significant amount of ionizing radiation in past 12 months;
  • Claustrophobia;
  • Contra-indications for Magnetic Resonance Imaging;
  • Pregnancy.

Healthy control participants:

Inclusion Criteria:

  • Healthy females (on hormonal contraception);
  • Dutch-speaking;
  • Right-handed;
  • Stable body weight with BMI of 18.5 - 25 kg/m².

Additional Exclusion Criteria:

  • Any psychiatric disorders;
  • Emotional or restraint eating behaviour.

Sites / Locations

  • Universitaire ziekenhuizen Leuven

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Bulimia Nervosa patients

Healthy controls

Arm Description

Bulimia Nervosa patient group: Assessment of dopamine release to food reward at baseline (before treatment) and to food reward after treatment.

Healthy control group: Assessment of dopamine release to food reward at baseline, for comparison with Bulimia Nervosa patients.

Outcomes

Primary Outcome Measures

Dopamine release to food reward in Bulimia Nervosa patients compared to healthy controls
Comparison of dopamine release to food reward between Bulimia Nervosa patients and healthy controls. Dopamine release is defined as changes in [18F]-Fallypride binding potential in the food reward condition, with a kinetic linearized simplified reference region model (LSSRM) model.
Change in dopamine release to food reward in Bulimia Nervosa patients before and after treatment
Comparison of dopamine release to food reward before and after inpatient treatment for Bulimia Nervosa. Dopamine release is defined as changes in [18F]-Fallypride binding potential in the food reward condition, with a kinetic linearized simplified reference region model (LSSRM) model.

Secondary Outcome Measures

Composite measure of metabolic hormone levels
Correlation between dopamine response to food reward and (changes in) metabolic hormone levels (ghrelin, motilin, glucagon-like peptide 1, peptide tyrosine tyrosine, leptin, and insulin)

Full Information

First Posted
March 5, 2018
Last Updated
March 13, 2018
Sponsor
Universitaire Ziekenhuizen KU Leuven
search

1. Study Identification

Unique Protocol Identification Number
NCT03471806
Brief Title
Dopamine Release to Food Reward in Bulimia Nervosa
Official Title
Dopamine Release to Food Reward in Bulimia Nervosa: an [18F]-Fallypride PET/MR Study.
Study Type
Interventional

2. Study Status

Record Verification Date
March 2018
Overall Recruitment Status
Unknown status
Study Start Date
February 16, 2018 (Actual)
Primary Completion Date
February 2020 (Anticipated)
Study Completion Date
May 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Universitaire Ziekenhuizen KU Leuven

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will assess the role of dopamine responses to food reward in Bulimia Nervosa patients, by performing simultaneous Positron Emission Tomography (PET) and Magnetic Resonance (MR) scanning. The dopamine response will be measured before and after treatment, and will be compared to healthy controls.
Detailed Description
Bulimia nervosa is a psychiatric eating disorder characterized by recurrent episodes of binge eating, followed by inappropriate compensatory behaviour. It is associated with a high disease burden and high rates of medical and psychiatric comorbidities. Only 50% of patients achieve long-term remission, indicating the need for a better understanding of the pathophysiology which can guide the development of new treatment options. There are strong indications for an involvement of the brain's dopaminergic reward system in Bulimia Nervosa, such as the presence of elevated craving for rewarding food and poorer impulse control. However, there is no clear evidence on the exact involvement of the reward system nor direct evidence of abnormal dopamine responses to food reward. Therefore, the current study will assess dopamine release and related brain activity to food reward in Bulimia Nervosa patients, by performing simultaneous Positron Emission Tomography (PET) and Magnetic Resonance (MR) scanning. Specifically, the investigators will compare dopamine release in Bulimia Nervosa patients to healthy controls, and assess the effect of successful treatment on the food reward response. To this end, 20 Bulimia Nervosa patients will participate in one PET-MR scan before the start of inpatient treatment and in a second PET-MR scan at the end of inpatient treatment. Additionally, PET-MR scans will be obtained from a group of 20 healthy control participants. All scan session will measure dopamine release to a combination of anticipatory (viewing high-calorie food images) and consummatory (drinking sips of chocolate milkshake) food reward and will be conducted in a fasted state. The scan sessions will consist of four blocks with a duration of 45 minutes each and 15 minute breaks in between. The first three blocks represent the 'control condition' and the fourth block the 'food reward condition'. During both sessions, blood samples will be collected at several time points to assess levels of metabolic hormones and their relation to food-induced dopamine release. This study aims to improve our understanding of the disease process underlying Bulimia Nervosa and to enable the identification of new and specific treatment targets at multiple levels of the gut-brain axis, including the dopamine system in the brain but also metabolic hormones and the interactions between both. Additionally, the results may have the potential to guide the optimisation of behavioural treatment approaches with a stronger focus on aberrant reward system responses.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Bulimia Nervosa, Food Reward
Keywords
Bulimia Nervosa, Eating disorder, Dopamine, Food, Reward, Positron Emission Tomography, Magnetic Resonance, Metabolic hormones

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Bulimia Nervosa patients
Arm Type
Experimental
Arm Description
Bulimia Nervosa patient group: Assessment of dopamine release to food reward at baseline (before treatment) and to food reward after treatment.
Arm Title
Healthy controls
Arm Type
Experimental
Arm Description
Healthy control group: Assessment of dopamine release to food reward at baseline, for comparison with Bulimia Nervosa patients.
Intervention Type
Behavioral
Intervention Name(s)
Food reward at baseline
Intervention Description
Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at baseline.
Intervention Type
Behavioral
Intervention Name(s)
Food reward after treatment
Intervention Description
Exposure to a combination of anticipatory (viewing high-calorie food images) and consummatory food reward (drinking sips of chocolate milkshake), at the end of inpatient treatment.
Primary Outcome Measure Information:
Title
Dopamine release to food reward in Bulimia Nervosa patients compared to healthy controls
Description
Comparison of dopamine release to food reward between Bulimia Nervosa patients and healthy controls. Dopamine release is defined as changes in [18F]-Fallypride binding potential in the food reward condition, with a kinetic linearized simplified reference region model (LSSRM) model.
Time Frame
Continuously over 225 minutes after onset scanning; at baseline (before onset treatment of patients)
Title
Change in dopamine release to food reward in Bulimia Nervosa patients before and after treatment
Description
Comparison of dopamine release to food reward before and after inpatient treatment for Bulimia Nervosa. Dopamine release is defined as changes in [18F]-Fallypride binding potential in the food reward condition, with a kinetic linearized simplified reference region model (LSSRM) model.
Time Frame
Continuously over 225 minutes after onset scanning; before and after inpatient treatment
Secondary Outcome Measure Information:
Title
Composite measure of metabolic hormone levels
Description
Correlation between dopamine response to food reward and (changes in) metabolic hormone levels (ghrelin, motilin, glucagon-like peptide 1, peptide tyrosine tyrosine, leptin, and insulin)
Time Frame
5 minutes before onset scanning and 45, 105, 165, 180, 195, 210 and 225 minutes after onset scanning

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Patients with Bulimia Nervosa: Inclusion Criteria: Diagnosed with Bulimia Nervosa based on DSM-5 criteria; Admission for inpatient treatment; Female (on hormonal contraception); Dutch-speaking; Right-handed; Body Mass Index (BMI) of 18.5 - 25 kg/m². Exclusion Criteria: Medical, neurological or other psychiatric disorders; Use of psychotropic medication in past 6 months; Use of cannabis or other drugs of abuse in past 12 months; Lactose-intolerance or food allergies; Vegetarian diet; Smoking; Consumption of more than 7 alcoholic units per week; Exposure to a significant amount of ionizing radiation in past 12 months; Claustrophobia; Contra-indications for Magnetic Resonance Imaging; Pregnancy. Healthy control participants: Inclusion Criteria: Healthy females (on hormonal contraception); Dutch-speaking; Right-handed; Stable body weight with BMI of 18.5 - 25 kg/m². Additional Exclusion Criteria: Any psychiatric disorders; Emotional or restraint eating behaviour.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lukas Van Oudenhove, Prof. dr.
Organizational Affiliation
Universitaire Ziekenhuizen KU Leuven
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitaire ziekenhuizen Leuven
City
Leuven
ZIP/Postal Code
3000
Country
Belgium

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Dopamine Release to Food Reward in Bulimia Nervosa

We'll reach out to this number within 24 hrs